alexa Effect of Orally Administered Microencapsulated FA-Producing L. fermentum on Markers of Metabolic Syndrome: An In Vivo Analysis | OMICS International | Abstract
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Effect of Orally Administered Microencapsulated FA-Producing L. fermentum on Markers of Metabolic Syndrome: An In Vivo Analysis

Jasmine Bhathena#, Catherine Tomaro-Duchesneau#, Christopher Martoni, Meenakshi Malhotra, Arun Kulamarva, Aleksandra Malgorzata Urbanska, Arghya Paul and Satya Prakash*

Biomedical Technology and Cell Therapy Research Laboratory, Departments of Biomedical Engineering, Physiology, and Artificial Cells and Organs Research Center, McGill University, Canada

#Equal contribution

*Corresponding Author:
Satya Prakash
Biomedical Technology and Cell Therapy Research Laboratory
Department of Biomedical Engineering and Artificial Cells and Organs Research Centre
Faculty of Medicine, McGill University
3775 University Street, Montreal
Québec, H3A 2B4, Canada
Tel: 1514-398-3676
Fax: 1514-398-7461
E-mail: [email protected]

Received date: April 25, 2012; Accepted date May 20, 2012; Published date: May 25, 2012

Citation: Bhathena J, Tomaro-Duchesneau C, Martoni C, Malhotra M, Kulamarva A, et al. (2012) Effect of Orally Administered Microencapsulated FA-Producing L. fermentum on Markers of Metabolic Syndrome: An In vivo Analysis. J Diabetes Metab S6:006. doi:10.4172/2155-6156.S6-006

Copyright: © 2012 Bhathena J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Abstract

Ferulic Acid (FA) is a natural phenolic acid produced by a number of lactic acid bacteria. FA has a number of beneficial properties, including: antioxidant activity, anti-tumorigenic properties and cholesterol-lowering capabilities. Our group has previously screened lactobacilli for FA production, and selected L. fermentum ATCC 11976 (L.f. 11976) as one of the best producers. Alginate-polylysine-alginate (APA) microencapsulation has proven successful for the oral delivery of this strain to the colon, where production of FA is greatest. The aim of this study was to investigate the role of APA microencapsulated L.f. 11976 to modulate markers of metabolic syndrome. The antioxidant activity, as a potential mechanism of action to treat/prevent metabolic syndrome of free and microencapsulated L.f.
11976 was quantified. A high-fat fed BioF1B Golden Syrian hamster model was used to investigate the effects of orally administered microencapsulated L.f. 11976 on markers of metabolic syndrome. Results demonstrate that the microencapsulated L.f. 11976 formulation greatly reduced the adiposity index (p = 0.0014), serum insulin (p = 0.0042), insulin resistance (p = 0.0096), glycosylated albumin (p = 0.00013), serum leptin (p = 0.048), serum uric acid (p =0.025) serum total cholesterol (p = 0.024), serum esterified cholesterol (p = 0.0328) and free non-esterified fatty acid (p = 0.029) levels in the treated animals. This research indicates that the probiotic L.f. 11976 microencapsulated formulation may significantly delay the onset of insulin resistance, hyperglycemia, hyperinsulinemia, dyslipidemia and obesity, indicating a lower risk of diabetes and cardiovascular disease. We propose and discuss the potential mechanism(s) of action by which FA is acting. With these in mind, further in vivo studies are required to validate the therapeutic effects of the formulation and to investigate the mechanism(s) of action by which the probiotic formulation is acting.

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version